Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

PHASE2CompletedINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

October 31, 2010

Conditions

HIV Infections

Interventions

DRUG

Vicriviroc

one 30 mg tablet QD

DRUG

emtricitabine and tenofovir disoproxil fumarate

one 200/300 combination tablet QD

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00551018 - Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875) | Biotech Hunter | Biotech Hunter